Prostate cancer is generally radiosensitive and external beam radiotherapy is effective in early-stage disease, which provided a good rationale for PSMA-RLT in metastatic prostate cancer [127]. The gene discussed is FOLH1; the disease is metastatic prostate carcinoma.